Head and Neck Cancer Trial, Recruiting (NCT07635641)

Head and Neck Cancer Trial, Recruiting NCT07635641 Sponsor: Istituto Clinico Humanitas Condition: Head and Neck Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07635641 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Head And Neck Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are 18 years of age or older
People whose ability to carry out daily activities is within a certain range of functioning, rated 0 to 2 on a standard medical scale (confirm with trial site)
People whose head and neck cancer recurrence has been confirmed through tissue testing, imaging, or both
People for whom proton therapy has been identified as an appropriate treatment
People who are willing and able to provide written consent to participate in the REPRO-HN study, in line with legal and ethical requirements, before the end of their radiotherapy treatment

Who may not be able to join:

People who are under 18 years of age
People whose daily functioning is rated above 3 on the standard medical activity scale, indicating a more limited ability to carry out daily tasks (confirm with trial site)
People whose life expectancy is estimated to be less than 3 months
People who are unable to provide informed consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Maria Ausilia Teriaca, MD, radiation oncologist, Humanitas Research Hospital IRCCS, Rozzano-Milan

Phone: +39 0282247461

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07635641

Sponsor: Istituto Clinico Humanitas

Phase: Not Applicable

Status: Recruiting

Condition: Head and Neck Cancer

Trial contact: +39 0282247461

More information: https://clinicaltrials.gov/study/NCT07635641

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are 18 years of age or older
People whose ability to carry out daily activities is within a certain range of functioning, rated 0 to 2 on a standard medical scale (confirm with trial site)
People whose head and neck cancer recurrence has been confirmed through tissue testing, imaging, or both
People for whom proton therapy has been identified as an appropriate treatment
People who are willing and able to provide written consent to participate in the REPRO-HN study, in line with legal and ethical requirements, before the end of their radiotherapy treatment

Who may not be able to join:

People who are under 18 years of age
People whose daily functioning is rated above 3 on the standard medical activity scale, indicating a more limited ability to carry out daily tasks (confirm with trial site)
People whose life expectancy is estimated to be less than 3 months
People who are unable to provide informed consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Istituto Clinico Humanitas

Registry

ClinicalTrials.gov

Start date

29 May 2026

Est. completion

1 June 2031

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Evaluation of toxicities profiles; Number of partecipants with disease free survival; number of patients with Loco-regional control; number of patient with distant metastasis free survival; Quality of life outcomes; assessment of treatment response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov